目的 探讨生脉胶囊联合达格列净片治疗慢性心力衰竭的疗效。方法 选取2023年3月—2024年12月在苏州明基医院收治的慢性心力衰竭患者共计86例，所有患者以随机数字表法分为对照组和治疗组，每组各43例。对照组患者口服达格列净片，1次/d，初始剂量1片/次，1周后调整为2片/次。治疗组患者在对照组治疗的基础上口服生脉胶囊，3粒/次，3次/d。两组患者的疗程为8周。对比两组患者的治疗效果、病情程度、运动耐力、生活质量、血清指标。结果 对照组的总有效率为69.77%，治疗组的总有效率为88.37%，两组比较差异显著（P＜0.05）。两组治疗后的Lee氏心衰评分、心功能不全生活质量量表（LHFQ）评分明显降低，6 min步行试验（6MWD）明显升高（P＜0.05）；治疗组治疗后的Lee氏心衰评分、LHFQ评分低于对照组，6MWD高于对照组（P＜0.05）。两组治疗后的血小板计数/淋巴细胞计数比值（PLR）及血清巨噬细胞炎症蛋白1α（MIP-1α）、脑钠肽（BNP）水平均明显降低（P＜0.05）；治疗组治疗后的PLR及血清MIP-1α、BNP水平均低于对照组（P＜0.05）。结论 生脉胶囊联合达格列净片可提高慢性心力衰竭的临床疗效，减轻心力衰竭病情，提高运动耐力和生活质量，机制与减轻心肌炎性损伤有关。

Objective To investigate the efficacy of Shengmai Capsules combined with Dapagliflozin Tablets in treatment of chronic heart failure. Methods 86 Patients with chronic heart failure admitted to Suzhou BenQ Hospital from March 2023 to December 2024 were selected. All patients were divided into control group and treatment group using a random number table method, with 43 cases in each group. The control group took Daggligin Tablets orally, once daily, with an initial dose of 1 tablets/time, which was adjusted to 2 tablets/time one week later. On the basis of treatment in the control group, the treatment group took Shengmai Capsules orally, 3 capsules/time, 3 times daily. Two groups of patients were treated for 8 weeks. The treatment efficacy, severity of illness, exercise endurance, quality of life, and serum indicators between two groups of patients were compared. Results The total effective rate of the control group was 69.77%, the total effective rate of the treatment group was 88.37%, and the difference between two groups was significant (P < 0.05). After treatment, the Lee’s heart failure score and Life with Heart Failure Questionnaire (LHFQ) scores significantly decreased, but the Six-Minute Walk Distance (6MWD) significantly increased in two groups (P < 0.05). The Lee’s heart failure score and LHFQ score of the treatment group were lower than those of the control group, but the 6MWD was higher than that of the control group (P < 0.05). After treatment, the platelet-to-lymphocyte ratio (PLR), serum levels of macrophage inflammatory protein 1α (MIP-1α), and brain natriuretic peptide (BNP) were significantly reduced in two groups (P < 0.05), and the PLR, serum levels of MIP-1α, and BNP in the treatment group were lower than those in the control group (P< 0.05). Conclusion Shengmai Capsules combined with Dapagliflozin Tablets can improve the efficacy of chronic heart failure, alleviate heart failure, enhance exercise tolerance and quality of life, which may be related to the reduction of myocardial inflammatory injury.

R972